others classify it more strictly
Primary outcome of ACR 20 response rate at week 12 were as follows: 37% for brodalumab 140mg (p=0.03), 39% for brodalumab 280mg (p=0.02), and 18% for placebo
CagriSema looks more familiar and potentially easier to contextualize because it builds on semaglutide plus amylin
It reduces local inflammation and supports tissue maintenance, but it works best alongside a broader treatment plan that addresses mechanical load
A medical evaluation may include history, medication review, physical examination, stool testing when appropriate, blood work, inflammatory markers, nutrient testing, thyroid review, metabolic markers, referral for gastroenterology evaluation, or other targeted steps depending on the symptoms